Haematologica · 2017 · 25 citations · 46 references
MedicineCancer BiologyOncologyInnate ImmunityMolecular OncologyOncogenesB Cell ActivationB Cell BiologyB-cell ResponsesLymphocyte ActivationMyc Family OncogenesActivated B Cell ResponsesC-myc RegulationEpstein-barr Virus LatencyMyc In LymphomaMyc OverexpressionNuclear Factor Kappa B ActivationNuclear Factor Kappa B SignalingTranscriptomic Biomarkers
While c-Myc dysregulation is constantly associated with highly proliferating B-cell tumors, nuclear factor (NF)-κB addiction is found in indolent lymphomas as well as diffuse large B-cell lymphomas, either with an activated B-cell like phenotype or associated with the Epstein-Barr virus. We raised the question of the effect of c-Myc in B cells with NF-κB activated by three different inducers: Epstein-Barr virus-latency III program, TLR9 and CD40. Induction of c-Myc overexpression increased proliferation of Epstein-Barr virus-latency III immortalized B cells, an effect that was dependent on NF-κB. Results from transcriptomic signatures and functional studies showed that c-Myc overexpression increased Epstein-Barr virus-latency III-driven proliferation depending on NF-κB. In vitro, induction of c-Myc increased proliferation of B cells with TLR9-dependant activation of MyD88, with decreased apoptosis. In the transgenic λc-Myc mouse model with c-Myc overexpression in B cells, in vivo activation of MyD88 by TLR9 induced splenomegaly related to an increased synthesis phase (S-phase) entry of B cells. Transgenic mice with both continuous CD40 signaling in B cells and the λc-Myc transgene developed very aggressive lymphomas with characteristics of activated diffuse large B-cell lymphomas. The main characteristic gene expression profile signatures of these tumors were those of proliferation and energetic metabolism. These results suggest that c-Myc is an NF-κB co-transforming event in aggressive lymphomas with an activated phenotype, activated B-cell like diffuse large B-cell lymphomas. This would explain why NF-κB is associated with both indolent and aggressive lymphomas, and opens new perspectives on the possibility of combinatory therapies targeting both the c-Myc proliferating program and NF-κB activation pathways in diffuse large B-cell lymphomas.
46
Oncogenically active MYD88 mutations in human lymphoma
Vu N. Ngo, Ryan M. Young, Roland Schmitz et al. · Nature · 2010 · 1.5K citations · Full text
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Steven P. Treon, Lian Xu, Guang Yang et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text
Mutations of multiple genes cause deregulation of NF-κB in diffuse large B-cell lymphoma
Mara Compagno, Wei Keat Lim, Adina Grunn et al. · Nature · 2009 · 1K citations
E. Britta-Mareen Traenckner, Heike L. Pahl, Timothy P. Henkel et al. · The EMBO Journal · 1995 · 1K citations · Full text
Arthur L. Shaffer, Xin Yu, Yunsheng He et al. · Immunity · 2000 · 867 citations · Full text